Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
RADBIO logo — Developing a therapeutic platform targeting TGF-beta, the "m...

RADBIO

Developing a therapeutic platform targeting TGF-beta, the "master regulator of fibrosis"

Founded 2018 United States San Carlos, United States 7 employees Biopharma, Biotechnology +2

General Information

Company Name RADBIO
Founded Year 2018
Location United States San Carlos, United States
Employees 7
Industries Biopharma, Biotechnology, Health Care +1
Social

BounceWatch is an independent company data service, not affiliated with RADBIO. To contact RADBIO, visit radbiopharm.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does RADBIO compare?

A PDF of RADBIO and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting RADBIO soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About RADBIO

RADBIO is a biopharmaceutical startup focusing on developing a therapeutic platform targeting TGF-beta, known as the "master regulator of fibrosis." Fibrosis, a significant factor in the cause of death for many diseases, lacks effective treatments to halt or reverse its progression, despite existing drugs that can delay it. RADBIO's innovative approach revolves around TGF-β, recognized as the primary driver of fibrosis. The company has made a breakthrough by identifying a new human protein, a unique soluble splice variant of the TGF-beta receptor 2, and is using genetic engineering to develop new assets. This enables them to tailor assets and delivery strategies according to specific indications, extending the potential applications and minimizing risk while enhancing value. Founded in 2018 and headquartered in the United States, RADBIO operates at the intersection of biopharma, biotechnology, healthcare, and pharmaceuticals. Currently, there is no information available regarding the last investment and associated investors.

Business keywords: Therapeutic platform, TGF-beta, Fibrosis treatment, Genetic engineering, Drug development, Biomolecule therapy, Research and development, Biomarkers, Biopharmaceutical, Diagnosis, Solid tumors, Neutralizing biomolecule, Delivery strategies

No funding data available for RADBIO yet.

RADBIO Alternatives & Competitors

View All Alternatives
RADBIO vs
RiboNova, Inc.
RiboNova, Inc. United States

Focused on Mitochondrial Disease & other serious rare diseases. R007 is our P2 ready asset, we also...

Venture round
7 employees
Biotechnology, Pharmaceutical
RADBIO vs
SonoThera
SonoThera United States

SonoThera is developing ultrasound-mediated nonviral genetic therapies.

Series A
54 employees
Biopharma, Biotechnology
RADBIO vs
Kelonia Therapeutics
Kelonia Therapeutics United States

Revolutionizing in vivo gene delivery to usher in a new era of genetic medicines.

Private Equity
74 employees
Biotechnology, Health Care
View all alternatives

FAQ About RADBIO

Developing a therapeutic platform targeting TGF-beta, the "master regulator of fibrosis"
RADBIO was founded in 2018.
RADBIO is headquartered in San Carlos, United States.
RADBIO operates in Biopharma, Biotechnology, Health Care and Pharmaceutical. Its work centres on Therapeutic platform, TGF-beta, Fibrosis treatment and Genetic engineering.
RADBIO has approximately 7 employees.
Top alternatives and competitors to RADBIO include RiboNova, Inc., SonoThera, Kelonia Therapeutics, Zelluna Immunotherapy, A2 Biotherapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
RADBIO and RiboNova, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for RADBIO, https://bouncewatch.com/company/radbio, updated 6 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes